1
|
Mariconda A, Iacopetta D, Sirignano M, Ceramella J, Costabile C, Pellegrino M, Rosano C, Catalano A, Saturnino C, El‐Kashef H, Aquaro S, Sinicropi MS, Longo P. N-Heterocyclic Carbene (NHC) Silver Complexes as Versatile Chemotherapeutic Agents Targeting Human Topoisomerases and Actin. ChemMedChem 2022; 17:e202200345. [PMID: 35904129 PMCID: PMC9804882 DOI: 10.1002/cmdc.202200345] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2022] [Revised: 07/28/2022] [Indexed: 01/09/2023]
Abstract
In recent years, the number of people suffering from cancer has risen rapidly and the World Health Organization and U.S. and European governments have identified this pathology as a priority issue. It is known that most bioactive anticancer molecules do not target a single protein but exert pleiotropic effects, simultaneously affecting multiple pathways. In our study, we designed and synthesized a new series of silver N-heterocyclic carbene (NHC) complexes [(NHC)2 Ag]+ [AgX2 ]- (X=iodide or acetate). The new complexes were active against two human breast cancer cell lines, MCF-7 and MDA-MB-231. These compounds showed multiple target actions as anticancer, by inhibiting in vitro the activity of the human topoisomerases I and II and interfering with the cytoskeleton dynamic, as also confirmed by in silico studies. Moreover, the antimicrobial activity of these silver complexes was studied against Gram-positive/negative bacteria. These dual properties provide a two-tiered approach, making these compounds of interest to be further deepened for the development of new chemotherapeutic agents.
Collapse
Affiliation(s)
- Annaluisa Mariconda
- Department of ScienceUniversity of BasilicataViale dell'Ateneo Lucano 1085100PotenzaItaly
| | - Domenico Iacopetta
- Department of PharmacyHealthand Nutritional SciencesUniversity of CalabriaVia Pietro Bucci87036Arcavacata diRendeItaly
| | - Marco Sirignano
- Department of Chemistry and BiologyUniversity of SalernoVia Giovanni Paolo II, 132Fisciano84084Italy
| | - Jessica Ceramella
- Department of PharmacyHealthand Nutritional SciencesUniversity of CalabriaVia Pietro Bucci87036Arcavacata diRendeItaly
| | - Chiara Costabile
- Department of Chemistry and BiologyUniversity of SalernoVia Giovanni Paolo II, 132Fisciano84084Italy
| | - Michele Pellegrino
- Department of PharmacyHealthand Nutritional SciencesUniversity of CalabriaVia Pietro Bucci87036Arcavacata diRendeItaly
| | - Camillo Rosano
- Biopolymers and Proteomics IRCCS Ospedale Policlinico San Martino – ISTLargo R. Benzi 1016132GenovaItaly
| | - Alessia Catalano
- Department of Pharmacy-Drug SciencesUniversity of Bari “Aldo Moro”Via Edoardo Orabona 470126BariItaly
| | - Carmela Saturnino
- Department of ScienceUniversity of BasilicataViale dell'Ateneo Lucano 1085100PotenzaItaly
| | | | - Stefano Aquaro
- Department of PharmacyHealthand Nutritional SciencesUniversity of CalabriaVia Pietro Bucci87036Arcavacata diRendeItaly
| | - Maria Stefania Sinicropi
- Department of PharmacyHealthand Nutritional SciencesUniversity of CalabriaVia Pietro Bucci87036Arcavacata diRendeItaly
| | - Pasquale Longo
- Department of Chemistry and BiologyUniversity of SalernoVia Giovanni Paolo II, 132Fisciano84084Italy
| |
Collapse
|
2
|
DeLeon TT, Almquist DR, Kipp BR, Langlais BT, Mangold A, Winters JL, Kosiorek HE, Joseph RW, Dronca RS, Block MS, McWilliams RR, Kottschade LA, Rumilla KM, Voss JS, Seetharam M, Sekulic A, Markovic SN, Bryce AH. Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. PLoS One 2020; 15:e0230306. [PMID: 32196516 PMCID: PMC7083309 DOI: 10.1371/journal.pone.0230306] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2019] [Accepted: 02/27/2020] [Indexed: 12/27/2022] Open
Abstract
Background CDKN2A and TP53 mutations are recurrent events in melanoma, occurring in 13.3% and 15.1% of cases respectively and are associated with poorer outcomes. It is unclear what effect CDKN2A and TP53 mutations have on the clinical outcomes of patients treated with checkpoint inhibitors. Methods All patients with cutaneous melanoma or melanoma of unknown primary who received checkpoint inhibitor therapy and underwent genomic profiling with the 50-gene Mayo Clinic solid tumor targeted cancer gene panel were included. Patients were stratified according to the presence or absence of mutations in BRAF, NRAS, CDKN2A, and TP53. Patients without mutations in any of these genes were termed quadruple wild type (QuadWT). Clinical outcomes including median time to progression (TTP), median overall survival (OS), 6-month and 12-month OS, 6-month and 12-month without progression, ORR and disease control rate (DCR) were analyzed according to the mutational status of CDKN2A, TP53 and QuadWT. Results A total of 102 patients were included in this study of which 14 had mutations of CDKN2A (CDKN2Amut), 21 had TP53 mutations (TP53mut), and 12 were QuadWT. TP53mut, CDKN2Amut and QuadWT mutational status did not impact clinical outcomes including median TTP, median OS, 6-month and 12-month OS, 6-month and 12-month without progression, ORR and DCR. There was a trend towards improved median TTP and DCR in CDKN2Amut cohort and a trend towards worsened median TTP in the QuadWT cohort. Conclusion Cell cycle regulators such as TP53 and CDKN2A do not appear to significantly alter clinical outcomes when immune checkpoint inhibitors are used.
Collapse
Affiliation(s)
- Thomas T. DeLeon
- Department of Hematology & Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America
| | - Daniel R. Almquist
- Department of Hematology & Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America
| | - Benjamin R. Kipp
- Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America
| | - Blake T. Langlais
- Department of Biostatistics, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America
| | - Aaron Mangold
- Department of Dermatology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America
| | - Jennifer L. Winters
- Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America
| | - Heidi E. Kosiorek
- Department of Biostatistics, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America
| | - Richard W. Joseph
- Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America
| | - Roxana S. Dronca
- Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America
| | - Matthew S. Block
- Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America
| | - Robert R. McWilliams
- Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America
| | - Lisa A. Kottschade
- Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America
| | - Kandelaria M. Rumilla
- Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America
| | - Jesse S. Voss
- Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America
| | - Mahesh Seetharam
- Department of Hematology & Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America
| | - Aleksandar Sekulic
- Department of Dermatology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America
- Mayo Clinic Cancer Center, Phoenix, Arizona, United States of America
| | - Svetomir N. Markovic
- Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America
| | - Alan H. Bryce
- Department of Hematology & Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America
- * E-mail:
| |
Collapse
|
3
|
Kalal BS, Upadhya D, Pai VR. Chemotherapy Resistance Mechanisms in Advanced Skin Cancer. Oncol Rev 2017; 11:326. [PMID: 28382191 PMCID: PMC5379221 DOI: 10.4081/oncol.2017.326] [Citation(s) in RCA: 63] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2016] [Revised: 02/24/2017] [Accepted: 02/27/2017] [Indexed: 12/20/2022] Open
Abstract
Melanoma is a most dangerous and deadly type of skin cancer, and considered intrinsically resistant to both radiotherapy and chemotherapy. It has become a major public health concern as the incidence of melanoma has been rising steadily over recent decades with a 5-year survival remaining less than 5%. Detection of the disease in early stage may be curable, but late stage metastatic disease that has spread to other organs has an extremely poor prognosis with a median survival of less than 10 months. Since metastatic melanoma is unresponsive to therapy that is currently available, research is now focused on different treatment strategies such as combinations of surgery, chemotherapy and radiotherapy. The molecular basis of resistance to chemotherapy seen in melanoma is multifactorial; defective drug transport system, altered apoptotic pathway, deregulation of apoptosis and/or changes in enzymatic systems that mediate cellular metabolic machinery. Understanding of alterations in molecular processes involved in drug resistance may help in developing new therapeutic approaches to treatment of malignant melanoma.
Collapse
Affiliation(s)
- Bhuvanesh Sukhlal Kalal
- Department of Biochemistry, Yenepoya Medical College, Mangaluru, India; Yenepoya Research Centre, Yenepoya University, Mangaluru, India
| | - Dinesh Upadhya
- Yenepoya Research Centre, Yenepoya University , Mangaluru, India
| | | |
Collapse
|
4
|
Ishitsuka A, Fujine E, Mizutani Y, Tawada C, Kanoh H, Banno Y, Seishima M. FTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression. Int J Mol Med 2014; 34:1169-74. [PMID: 25109763 DOI: 10.3892/ijmm.2014.1882] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2014] [Accepted: 07/31/2014] [Indexed: 11/06/2022] Open
Abstract
Sphingosine kinase (SK), a key enzyme in sphingosine-1-phosphate (S1P) synthesis, is known to be overexpressed in various types of cancer cells. The effects of anticancer agents on SK1/S1P signaling have not yet been fully assessed in melanoma cells. In the present study, we investigated the effects of the combination of FTY720, an S1P receptor antagonist, and cisplatin, a DNA-damaging agent, on the induction of the death of human melanoma cells, as well as the molecular mechanisms involved. The viability of various human melanoma cell lines was examined following treatment with anticancer drugs. The cisplatin-resistant SK-Mel-28 and cisplatin-sensitive A375 cell lines were selected for this analysis. Protein expression and apoptotic rates were evaluated by western blot analysis following treatment with cisplatin and/or FTY720. Following treatment with a combination of FTY720 and cisplatin, cell viability significantly decreased and the expression of apoptosis-associated cleaved poly(ADP-ribose) polymerase (PARP) was significantly higher in comparison to treatment with cisplatin alone in the SK-Mel-28 cells. In addition, the combination of FTY720 and cisplatin reduced the protein expression of SK1 and the phosphorylation levels of phosphoinositide 3-kinase (PI3K), Akt and mTOR in the SK-Mel-28 cells; the expression of epidermal growth factor receptor (EGFR) was also markedly reduced. These findings suggest that FTY720 and cisplatin synergistically induce cell death through the downregulation of the PI3K/Akt/mTOR pathway and the decrease in EGFR expression in SK-Mel-28 cells. Thus, the combination of FTY720 and cisplatin may have therapeutic potential for chemotherapy-resistant melanoma, and the effects are likely exerted through the downregulation of S1P signaling.
Collapse
Affiliation(s)
- Asako Ishitsuka
- Department of Dermatology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan
| | - Etsuko Fujine
- Department of Dermatology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan
| | - Yoko Mizutani
- Department of Dermatology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan
| | - Chisato Tawada
- Department of Dermatology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan
| | - Hiroyuki Kanoh
- Department of Dermatology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan
| | - Yoshiko Banno
- Department of Dermatology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan
| | - Mariko Seishima
- Department of Dermatology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan
| |
Collapse
|
5
|
Egelston C, Kurkó J, Besenyei T, Tryniszewska B, Rauch TA, Glant TT, Mikecz K. Suppression of dendritic cell maturation and T cell proliferation by synovial fluid myeloid cells from mice with autoimmune arthritis. ACTA ACUST UNITED AC 2013; 64:3179-88. [PMID: 22492217 DOI: 10.1002/art.34494] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To determine whether myeloid cells (such as granulocytes) present in the synovial fluid (SF) of arthritic joints have an impact on adaptive immunity. Specifically, we investigated the effects of SF cells harvested from the joints of mice with proteoglycan-induced arthritis (PGIA), on dendritic cell (DC) maturation and antigen-specific T cell proliferation. METHODS We monitored DC maturation (MHCII and CD86 expression) by flow cytometry upon coculture of DCs with SF cells or spleen myeloid cells from mice with PGIA. The effects of these myeloid cells on T cell proliferation were studied using T cells purified from PG-specific T cell receptor (TCR)-transgenic (Tg) mice. Phenotype analysis of myeloid cells was performed by immunostaining, reverse transcription-polymerase chain reaction, Western blotting, and biochemical assays. RESULTS Inflammatory SF cells significantly suppressed the maturation of DCs upon coculture. PG-TCR-Tg mouse T cells cultured with antigen-loaded DCs showed dramatic decreases in proliferation in the presence of SF cells. Spleen myeloid cells from arthritic mice did not have suppressive effects. SF cells were unable to suppress CD3/CD28-stimulated proliferation of the same T cells, suggesting a DC-dependent mechanism. SF cells exhibited all of the characteristics of myeloid-derived suppressor cells (MDSCs) and exerted suppression primarily through the production of nitric oxide and reactive oxygen species by granulocyte-like cells. CONCLUSION SF in the joints of mice with PGIA contains a population of granulocytic MDSCs that potently suppress DC maturation and T cell proliferation. These MDSCs have the potential to limit the expansion of autoreactive T cells, thus breaking the vicious cycle of autoimmunity and inflammation.
Collapse
Affiliation(s)
- Colt Egelston
- Rush University Medical Center, Chicago, Illinois 60612, USA
| | | | | | | | | | | | | |
Collapse
|